Institute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar, Orissa, India.
Curr Drug Deliv. 2011 Jan;8(1):45-58. doi: 10.2174/156720111793663606.
Receptor-mediated tumor targeting has received major attention in the field of cancer drug delivery in the past few years. Receptors, as molecular target has opened new opportunities for cellular or intracellular targeting of drug loaded delivery systems conjugated with targeting moieties i.e. ligand. This receptor mediated targeting of cancer drug through nano carrier systems to cancerous tissue offer protection and improves the pharmacokinetics of various drugs and help to overcome the systemic toxicity and adverse effects that result from the non-selective nature of most current cancer therapeutic agents. The article reviews the scope of receptor mediated targeting of anticancer drug loaded in various nanocarriers and also summarize recent perspective and challenges in the field of nanocarrier-aided drug delivery and drug targeting for cancer therapy.
近年来，受体介导的肿瘤靶向在癌症药物输送领域受到了极大关注。作为分子靶点，受体为与靶向部分（即配体）缀合的载药输送系统的细胞内或细胞靶向提供了新的机会。通过纳米载体系统将抗癌药物靶向递送至癌组织中的这种受体介导的靶向作用，为各种药物提供了保护并改善了药代动力学，有助于克服大多数当前癌症治疗剂的非选择性所导致的全身毒性和副作用。本文综述了各种纳米载体中负载的抗癌药物的受体介导靶向作用的范围，并总结了纳米载体辅助药物输送和癌症治疗药物靶向领域的最新观点和挑战。
